Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
The goal of the Innovative Medicines Initiative 2 (IMI 2) is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI. Like IMI, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe’s pharmaceutical industry.
Característiques principals
This Call is being run in a two stage submission and evaluation process.
Short proposals for this call can only be done through the Horizon 2020 Participant Portal:
http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/calls/h2020-jti-imi2-2017-13-two-stage.html
Característiques principals
Topics of the 13th Call:
  • Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
  • Genome-environment interactions in inflammatory skin disease
  • The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
  • Mitochondrial dysfunction in neurodegeneration
  • Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative
  • A sustainable European induced pluripotent stem cell platform
  • Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
  • Human tumour microenvironment immunoprofiling
  • ConcePTION – Continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
  • Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
  • Translational safety biomarker pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
  • Pilot programme on a clinical compound bank for repurposing – this programme contains four topics on cardiovascular diseases and diabetes; respiratory diseases; neurodegenerative diseases; and rare/orphan diseases
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00.
    • Carol Barnwell, cbarnwell@imim.es. Ext.: 1670
    • Marta López, mlopez4@imim.es Ext.: 1576
    Convocatòria (URL)
    http://www.imi.europa.eu/apply-funding/open-calls/imi2-call-13
    Dotació
    IMI JU collaborative projects are implemented through a co-financing scheme. The IMI JU grants financial support to the eligible entities, while the other entities (including the EFPIA companies) participate in the project with their own resources.
    The EU contribution ranges from 1.200.000 – 25.500.000 € depending on the topic

    Arxius

    Arxiu
    1. IMI2_C13_TOPICS TEXT_EN.pdf